Impact of the Covid-19 pandemic on the diagnosis & treatment of prostate cancer: Updated findings from the NPCA

Commissioned by **HQIP** on behalf of **NHS England** and **Welsh Government**

Based at the **Clinical Effectiveness Unit**,
Royal College of Surgeons / London School of Hygiene & Tropical Medicine

Clinical leadership provided by **BAUS** and **BUG**

Data partners: **National Cancer Registry and Analysis Service**, **Wales Cancer Network**

RCS

NDRS
NATIONAL DISEASE REGISTRATION SERVICE

LONDON SCHOOL of HYGIENE &TROPICAL MEDICINE

HQIP
Healthcare Quality Improvement Partnership

BUG

THE BRITISH ASSOCIATION OF UROLOGICAL SURGEONS

www.npca.org.uk **npca@rcseng.ac.uk**

NPCA
National Prostate Cancer Audit

Impact of the Covid-19 pandemic on the diagnosis & treatment of prostate cancer: Updated findings from the NPCA

Joanna Dodkins

NPCA Clinical Fellow

NPCA Project Team:

NPCA Clinical Leads: Noel Clarke / Heather Payne

NPCA Clinicians: Ajay Aggarwal / Paul Cathcart / Joanna Dodkins / Matt Parry

Arun Sujenthiran / Brendan Berry / Arjun Nathan

RCS-LSHTM: Jan Van der Meulen / Julie Nossiter / Mel Morris / Adrian Cook

BJU Int 2022 doi:10.1111/bju.15699

Original Article

BJUI
BJU International

Impact of the COVID-19 pandemic on the diagnosis and treatment of men with prostate cancer

Julie Nossiter[1,2], Melanie Morris[1,2], Matthew G. Parry[1,2], Arunan Sujenthiran[2], Paul Cathcart[3], Janvan der Meulen[1,†], Ajay Aggarwal[1,4,5,†], Heather Payne[6,†] and Noel W. Clarke[7,†]

[1]Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, [2]Clinical Effectiveness Unit, Royal College of Surgeons of England, [3]Department of Urology, Guy's and St Thomas' NHS Foundation Trust, [4]Department of Radiotherapy, Guy's and St Thomas' NHS Foundation Trust, [5]Department of Cancer Epidemiology, Population, and Global Health, King's College London, [6]Department of Oncology, University College London Hospitals NHS Foundation Trust, London, and [7]Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK

†Joint senior authors.

NPCA Annual Report 2022: Impact of COVID-19 analysis

New for the 2022 report:

1. COVID impact reporting for **Wales**

   Using data up to end March 2021

2. Update: COVID impact reporting for **England**

   Using data up to end December 2021

Aim of NPCA Impact of COVID-19 analysis

Evaluate the impact on the **diagnosis** and **treatment** of men with prostate cancer

1. What is the extent of the prostate cancer **diagnostic** backlog in England and Wales?

2. To what extent have **surgery** and **radiotherapy** services been disrupted in England and Wales?

3. Was access to **systemic therapies** disrupted and has the type of therapy changed since the COVID-19 pandemic in England?

Methods for NPCA Impact of COVID-19 analysis

Diagnostic and treatment activity in 2020 and 2021 was determined across all NHS hospital providers of PCa care in England and Wales

- compared with the same calendar periods in 2019

For England

- Using RCRD up to end **December 2021**

For Wales

- Using standard data up to end **March 2021**

Key Findings

COVID impact in England

(data 1 January 2019 - 31 December 2021)

Some evidence of recovery in 2021

COVID impact in England: Variation in diagnoses

By region



Overall

- **7% below** 2019 figures (24% below in 2020)

COVID impact in England: Change in RPs

By region



Overall

- **18% below** 2019 figures (22% below in 2020)

COVID impact in England: Change in RT

By region



Overall

- **18% below** 2019 figures (13% below in 2020)
- Maintained increased use of hypofractionation

COVID impact in England: Change systemic therapy

By region



Overall

- **40% above** 2019 figures (data available for England only)

COVID impact in England: Change in docetaxel

By region



- Docetaxel use did not return to pre-pandemic levels

COVID impact in England: Change in enzalutamide

By region



Key Findings

COVID impact in Wales

(data 1 January 2019 - 31 March 2021)

Similar to patterns seen in England in 2020

COVID impact in Wales: variation in diagnoses

By SMDT



Overall

- Reached **52% reduction** in April-June 2020
- **29% reduction** by January-March 2021

COVID impact in Wales: change in RPs

By SMDT



Overall

- **43% reduction** at April-June 2020; **4%** in Oct-Dec 2020
- **52% reduction** by January-March 2021

COVID impact in Wales: change in RT

By SMDT



Overall

- **67% reduction** in April-June 2020; recovery in Q3/4 2020
- **28% reduction** by Jan-Mar 2021

Summary

- Evidence of **disruption** during the pandemic but also **recovery** particularly for diagnostic pathways
- Number of treatments still lags behind 2019 numbers but will reflect **fewer diagnoses**
- Variation across regions and SMDTs apparent
- Availability of enzalutamide ensured proportion receiving adjunct treatments to ADT has increased

THANK YOU

www.npca.org.uk

npca@rcseng.ac.uk

NPCA
National Prostate Cancer Audit